These pathways as well as innate and adaptive immune responses demonstrated by T-cell activation have become an area of active research, with antibodies against CTLA-4 and PD-1 showing clinical efficacy and anti-tumour activity. The gene discussed is CTLA4; the disease is neoplasm.